301 related articles for article (PubMed ID: 20888135)
21. Serum tumor markers CEA, CYFRA21-1, and CA-125 are associated with worse prognosis in advanced non-small-cell lung cancer (NSCLC).
Cedrés S; Nuñez I; Longo M; Martinez P; Checa E; Torrejón D; Felip E
Clin Lung Cancer; 2011 May; 12(3):172-9. PubMed ID: 21663860
[TBL] [Abstract][Full Text] [Related]
22. Can serum markers be used to predict acute and late toxicity in patients with lung cancer? Analysis of RTOG 91-03.
Hartsell WF; Scott CB; Dundas GS; Mohiuddin M; Meredith RF; Rubin P; Weigensberg IJ
Am J Clin Oncol; 2007 Aug; 30(4):368-76. PubMed ID: 17762437
[TBL] [Abstract][Full Text] [Related]
23. [Prognosis of locally advanced non small cell lung cancer treated with three dimentional conformal radiotherapy].
Zhu XZ; Wang LH; Ou GF; Zhou ZM; Chen DF; Xiao ZF; Feng QF; Zhang HX; Wang M; Yin WB
Zhonghua Zhong Liu Za Zhi; 2007 Oct; 29(10):748-53. PubMed ID: 18396686
[TBL] [Abstract][Full Text] [Related]
24. Tumor volume is a prognostic factor in non-small-cell lung cancer treated with chemoradiotherapy.
Alexander BM; Othus M; Caglar HB; Allen AM
Int J Radiat Oncol Biol Phys; 2011 Apr; 79(5):1381-7. PubMed ID: 20605346
[TBL] [Abstract][Full Text] [Related]
25. CYFRA 21-1 and CEA are independent prognostic factors in 153 operated stage I NSCLC patients.
Muley T; Dienemann H; Ebert W
Anticancer Res; 2004; 24(3b):1953-6. PubMed ID: 15274383
[TBL] [Abstract][Full Text] [Related]
26. Predictive role of CEA and CYFRA 21-1 in patients with advanced-stage NSCLC treated with erlotinib.
Fiala O; Pesek M; Finek J; Benesova L; Minarik M; Bortlicek Z; Topolcan O
Anticancer Res; 2014 Jun; 34(6):3205-10. PubMed ID: 24922695
[TBL] [Abstract][Full Text] [Related]
27. The prognostic value of carcinoembryonic antigen in T1N1M0 and T2N1M0 non-small cell carcinoma of the lung.
Fukai R; Sakao Y; Sakuraba M; Oh S; Shiomi K; Sonobe S; Saitoh Y; Miyamoto H
Eur J Cardiothorac Surg; 2007 Sep; 32(3):440-4. PubMed ID: 17643308
[TBL] [Abstract][Full Text] [Related]
28. A pilot study on potential plasma hypoxia markers in the radiotherapy of non-small cell lung cancer. Osteopontin, carbonic anhydrase IX and vascular endothelial growth factor.
Ostheimer C; Bache M; Güttler A; Kotzsch M; Vordermark D
Strahlenther Onkol; 2014 Mar; 190(3):276-82. PubMed ID: 24322994
[TBL] [Abstract][Full Text] [Related]
29. Prognostic significance of tumour marker index based on preoperative CEA and CYFRA 21-1 in non-small cell lung cancer.
Tomita M; Shimizu T; Ayabe T; Yonei A; Onitsuka T
Anticancer Res; 2010 Jul; 30(7):3099-102. PubMed ID: 20683062
[TBL] [Abstract][Full Text] [Related]
30. Optimal combination of seven tumour markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer.
Ando S; Kimura H; Iwai N; Shima M; Ando M; Kuriyama T
Anticancer Res; 2001; 21(4B):3085-92. PubMed ID: 11712815
[TBL] [Abstract][Full Text] [Related]
31. Sequential chemoradiation therapy with vinorelbine, ifosfamide, and cisplatin in stage IIIB non-small cell lung cancer: a phase II study.
Baldini E; Silvano G; Tibaldi C; Campoccia S; Cionini L; Conte P
Semin Oncol; 2000 Feb; 27(1 Suppl 1):28-32. PubMed ID: 10697041
[TBL] [Abstract][Full Text] [Related]
32. CYFRA 21-1 in the follow-up of inoperable non-small cell lung cancer patients treated with chemotherapy.
Ebert W; Muley T
Anticancer Res; 1999; 19(4A):2669-72. PubMed ID: 10470217
[TBL] [Abstract][Full Text] [Related]
33. Randomized phase III trial comparing bexarotene (L1069-49)/cisplatin/vinorelbine with cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT I.
Ramlau R; Zatloukal P; Jassem J; Schwarzenberger P; Orlov SV; Gottfried M; Pereira JR; Temperley G; Negro-Vilar R; Rahal S; Zhang JK; Negro-Vilar A; Dziewanowska ZE
J Clin Oncol; 2008 Apr; 26(11):1886-92. PubMed ID: 18398154
[TBL] [Abstract][Full Text] [Related]
34. Prognostic markers for stage I non-small cell lung cancer.
Mizuguchi S; Nishiyama N
Lung Cancer; 2008 Feb; 59(2):274-5. PubMed ID: 18055061
[No Abstract] [Full Text] [Related]
35. Tumor volume combined with number of positive lymph node stations is a more important prognostic factor than TNM stage for survival of non-small-cell lung cancer patients treated with (chemo)radiotherapy.
Dehing-Oberije C; De Ruysscher D; van der Weide H; Hochstenbag M; Bootsma G; Geraedts W; Pitz C; Simons J; Teule J; Rahmy A; Thimister P; Steck H; Lambin P
Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):1039-44. PubMed ID: 17889446
[TBL] [Abstract][Full Text] [Related]
36. [Detection and diagnostic value of serum carcinoembryonic antigen and cytokeratin 19 fragment in lung cancer patients].
Hang ZQ; Zheng MF; Huang JH
Zhonghua Zhong Liu Za Zhi; 2011 Nov; 33(11):847-9. PubMed ID: 22335951
[TBL] [Abstract][Full Text] [Related]
37. Increased CYFRA 21-1 and CEA levels are negative predictors of outcome in p-stage I NSCLC.
Muley T; Dienemann H; Ebert W
Anticancer Res; 2003; 23(5b):4085-93. PubMed ID: 14666606
[TBL] [Abstract][Full Text] [Related]
38. [Detection and prognostic significance of micrometastasis in peripheral blood of patients with non-small cell lung cancer treated by chemo-radiation therapy].
Chen TF; Jiang GL; Zhang YQ; Wang LJ; Fu XL; Qian H; Wu KL; Zhao S
Zhonghua Zhong Liu Za Zhi; 2007 May; 29(5):365-8. PubMed ID: 17892133
[TBL] [Abstract][Full Text] [Related]
39. Pulmonary resection after curative intent radiotherapy (>59 Gy) and concurrent chemotherapy in non-small-cell lung cancer.
Sonett JR; Suntharalingam M; Edelman MJ; Patel AB; Gamliel Z; Doyle A; Hausner P; Krasna M
Ann Thorac Surg; 2004 Oct; 78(4):1200-5; discussion 1206. PubMed ID: 15464470
[TBL] [Abstract][Full Text] [Related]
40. Comparison of serum growth factors and tumor markers as prognostic factors for survival in non-small cell lung cancer.
Nieder C; Andratschke N; Jeremic B; Molls M
Anticancer Res; 2003; 23(6D):5117-23. PubMed ID: 14981976
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
